Respiratory Infections

Johns Hopkins data suggest men are being hospitalized more frequently with infection, and are facing more severe outcomes.

A UK health authority representative discussed the possibility of a fall season booster to prevent another winter surge of cases.

Though small in scale and still cautious, the new advisory reflects confidence in SARS-CoV-2 mitigation among a more vaccinated population.

The frontline assay from Abbott will help differentiate among 4 respiratory viruses in real-time.

The statement comes on the same day as a rare production agreement between pharmaceutical rivals, and Texas' announced lift of spread mitigation measures.

Courtesy of HCPLive, here's a look at 3 new pandemic talking points covered at the annual allergy and asthma meeting.

How observed changes in SARS-CoV-2 lineage have warranted heightened priority, and why sequencing deserves better resourcing beyond the pandemic.

A team of cross-country investigators discuss their coordinated tracking of a new variant in the US earlier this year.

The new trial comes at a time when the FDA has provided guidance on navigating immunogenicity trials for vaccines designed against more transmissible SARS-CoV-2 strains.

Supporting EUA data for the one-shot vaccine candidate showed Americans fared best in a 40,000-participant, international trial.

This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.

The government-funded trial will seek to interpret the virus' transmissibility and infection, in order to inform vaccination and treatment strategies.

In this era of increasingly mobile and connected populations, it is possible for an infection to spread around the world in 24 to 48 hours.

Preprint data show a US-based variant has come to represent more than 27% and 11% of all sequenced genomes in Louisiana and New Mexico, respectively, through mid-January.

A new study suggests nursing homes with more people of color are actually at three-fold greater risk of COVID-19 mortality.

The EUA follows the authorization for lone therapy bamlanivimab for adults and children at risk of severe COVID-19.

Implications for antimicrobial use and antimicrobial resistance.

New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.

Cohort data shows 87% of infants born to mothers with asymptomatic or symptomatic COVID-19 have developed antibodies at birth.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

New systematic review data suggest most patients who test positive without symptoms will remain asymptomatic over time.

A France-based assessment of the IL-1 inhibitor was ended early on the recommendation of the safety monitoring board early this year.

Avian flu outbreaks have been detected in countries all over the world, but influenza activity in humans remains uncharacteristically low for this point in the season.